Home PurpleBook 125509 Anthim Purple Book BLA 125509
BLA number 125509
Proprietary names Anthim
Proper names obiltoxaximab
Applicant Elusys Therapeutics, Inc.
Center CDER
First observed release 2020-05-01
Latest observed release 2026-06-01
Newest archive release 2026-06-01
FDA patent list No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage Present in newest release Latest Known Product Presentations# Product, Proprietary name, Proper name table Product Proprietary name Proper name License type Strength Dosage form Route Presentation Marketing Licensure Approval Patent list provided 001 Anthim obiltoxaximab 351(a) 600MG/6ML (100MG/ML) Injection Intravenous Single-Dose Vial Rx Licensed 2016-03-18
Published Patent List# No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events# Release, Event, Product table Release Event Product Name License type Status Applicant 2020-08-01 U 001 Anthim 351(a) Rx Elusys Therapeutics, Inc. 2020-05-01 R 001 Anthim 351(a) Rx Elusys Therapeutics, Inc.
Observed Product State History# Release, Product, Name table Release Product Name License type Marketing Licensure Approval 2020-05-01 001 Anthim 351(a) Rx Licensed 2016-03-18
Drug identity information. FDA.report links public drug records from RxNav, DailyMed, FDA NDC, Drugs@FDA, and related public sources where available. This page is informational only and is not medical, prescribing, or regulatory advice.